Skip to content
FJ ⭐️⭐️+⭐️· @pistoto2017 · X·· 12 hours agoScore70

DELLPHI-305

Body

Let’s take a look at #DeLLphi-305: the trial yields poor results in the "Americas," so you bring in a large number of Asian patients (±40%) #sclc #ESMO26 Opinions??? @StephenVLiu @drshieldsmd @Tony_Calles @LuisPaz_Ares @lungoncdoc @Annechiangmd @LealTiciana @latina @MartinReck2

218 views · 4 likes · 1 repost · 2 replies

Conference abstracts
LBA3matched by Presidential Symposium I

Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial

https://esmocongress.esmo.org
Replies in this thread
  1. FJ ⭐️⭐️+⭐️@pistoto2017

    #sclc #esmo26 #tarlatamab

  2. Cosas De Bolsa@BolsaCosas

    @pistoto2017 Que listos son los de #Amgen siempre modificando los ensayos a su favor, claro, pero tan descarado...tan descarado. Es que es increíble que en un estudio tan importante hagan éstas cosas

Source: FJ ⭐️⭐️+⭐️ · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org